# AEON Biopharma (AEON) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AEON
## Company Profile
- Ticker: AEON
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 0.275 USD
- Market cap: 19735669.692199998 USD
- Last updated: 2026-08-12
## Business Overview
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology. The investment case centers on whether the company can turn a highly specialized product profile into a durable franchise.
## Why The Stock Is Moving

As of Aug 12, 2026, AEON closed up 0.73% at $0.2750. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, AEON sits in the specialty therapeutics segment. Its profile is shaped more by product execution and regulatory positioning than by broad pipeline breadth.

## Business Model

AEON depends on clinical progress, commercialization strategy, and the ability to convert a focused asset base into repeatable revenue. Investors typically watch launch timing, commercial access, and strategic financing decisions.

## Landscape Position

AEON sits in a narrow but catalyst-sensitive corner of biotech where a single program can drive most of the valuation. Compared with larger peers, the stock is more exposed to execution risk and inflection-point revaluation.

## Future Catalysts

- The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.

## Recent News
- 2025-05-23 20:05 EST — [AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711](https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-s-24111f7c) — Source: AEON Biopharma
- 2025-05-19 20:05 EST — [AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025](https://biopharmsignal.com/news/AEON/aeon-biopharma-to-present-at-the-aegis-capital-corp-virtual-conference-2025-e6c5b5d1) — Source: AEON Biopharma
- 2025-05-14 20:05 EST — [AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/AEON/aeon-biopharma-reports-first-quarter-2025-financial-results-and-provides-corpora-0ada1efe) — Source: AEON Biopharma
- 2025-04-25 20:05 EST — [AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance](https://biopharmsignal.com/news/AEON/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-comp-3d1e3467) — Source: AEON Biopharma
- 2025-04-21 20:05 EST — [AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer](https://biopharmsignal.com/news/AEON/aeon-biopharma-appoints-industry-veteran-rob-bancroft-as-chief-executive-officer-deed6b7a) — Source: AEON Biopharma